US equities
|
MU
$878.81
▼-5.63%
NVDA
$214.68
▼-1.17%
TSLA
$354.68
▼-2.14%
AAPL
$343.41
▲+0.41%
META
$706.88
▼-4.05%
SPCX
$144.50
▼-2.77%
SNDK
$1,303.36
▼-6.56%
MSFT
$528.79
▼-1.97%
MU
$878.81
▼-5.63%
NVDA
$214.68
▼-1.17%
TSLA
$354.68
▼-2.14%
AAPL
$343.41
▲+0.41%
META
$706.88
▼-4.05%
SPCX
$144.50
▼-2.77%
SNDK
$1,303.36
▼-6.56%
MSFT
$528.79
▼-1.97%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
9.405
-0.245 (-2.54%)
Delayed Quote
Updated: 3:35 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
October 14, 2026
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
September 30, 2026
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
August 12, 2026
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Announces Changes to Its Board of Directors
June 12, 2026
From
Atara Biotherapeutics, Inc.
Via
Business Wire
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
May 22, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
May 22, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
May 21, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 21, 2026
From
Schall Law
Via
GlobeNewswire
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
May 20, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
May 19, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
May 18, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 18, 2026
From
Schall Law
Via
GlobeNewswire
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
May 14, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 13, 2026
From
Schall Law
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
May 12, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
May 12, 2026
From
Atara Biotherapeutics, Inc.
Via
Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
May 11, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 11, 2026
From
Schall Law
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 08, 2026
From
Schall Law
Via
GlobeNewswire
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
May 07, 2026
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
May 05, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
May 05, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 05, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
May 02, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 01, 2026
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 28, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
April 25, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
